********* Sunnyvale, March 11, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC), a life sciences and personalized medicine company, increases weekly guidance for medical billing associated with its physician-prescribed allergy testing services from $1,000,000 ($1 million) per week as presented in the December 31 2018 CEO Letter to Shareholders, to $2,000,000 ($2 million) per week effective immediately. The 100% weekly guidance increase from $1 million to $2 million per week for fiscal year 2019 (FY2019) is based on medical billing growth during the first quarter of FY2019, the number of new clinics being added to our Patient Data Solutions portal, and the rate of allergy testing services adoption in the marketplace. Arrayit allergy testing services, which empower doctors to identify, manage and treat allergy and asthma using simple finger stick blood sampling, are raising the standard of care among the estimated 60 million Americans who report annual allergy symptoms.
Arrayit recently completed an allergy testing pilot program for a top retail chain, established a nationwide network of 1,700 allergy sales professionals, met with top officials at the United States Food and Drug Administration (FDA) regarding approval of a major product line, fulfilled an FDA clinical instrumentation contract, received approval for in-store promotions by a major retailer, announced allergy testing partnerships with major allergy therapeutics providers, received approval for direct Medicare billing by the Centers for Medicare and Medicaid Services, launched the Patient Data Solutions allergy portal for doctors and clinics, celebrated 25 years of company operations, announced an allergy testing services agreement with a major health and wellness provider, provided a letter to shareholders from the company’s Chief Executive Officer, aced four consecutive rounds of proficiency testing, received endorsement by First Pediatrics Medical Group, doubled the number of clinics in its nationwide network to more than 400, and announced in-network allergy testing services contracting with a top five commercial healthcare benefits company. The contribution of the $2 million per week increased guidance for allergy testing services billing to revenues and earnings will be detailed in the company’s upcoming quarterly and annual FY2019 financial filings.
